Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AbbVie (ABBV), Genentech (RHHBY) Leukemia Drug Wins Breakthrough Status Tag

A promising new blood cancer therapy from AbbVie (ABBV) and Genentech (RHHBY) that snagged headlines in early December for unexpectedly high rates of response in clinical trial patients has now been granted breakthrough status from the U.S. Food and Drug Administration (FDA), the companies said Thursday. The investigational drug, dubbed venetoclax, is an inhibitor of […]

Read More »

Safety switches may redeem potent CAR T cancer therapies

(Reuters) – New therapies that clinical data show can eliminate blood cancers such as leukemia and lymphoma in 40 percent to 90 percent of patients may have to be genetically modified to include a switch that shields healthy cells from attack. The therapies could generate tens of billions of dollars in annual sales for drugmakers […]

Read More »

PlasmaTech Biopharmaceuticals Announces Agreement to Acquire Abeona Therapeutics LLC

DALLAS, TX and CLEVELAND, OH and NEW YORK, NY–(Marketwired – May 06, 2015) – Company is well positioned to execute on its strategy to become a leader in cell therapy and gene therapy for rare diseases Abeona’s preclinical studies have demonstrated promising efficacy in cognitive function, motor, and survival in Sanfilippo Syndrome (MPS IIIA and […]

Read More »

Industry Collaborations Are Key CCRM Strategy to Drive Commercialization in Regenerative Medicine Field

TORONTO, ONTARIO–(Marketwired – May 6, 2015) – In under four years, the Centre for Commercialization of Regenerative Medicine (CCRM) has established an industry consortium of 45 companies, from around the globe, including Big Pharma and Canadian startups, that cover the key sectors in regenerative medicine (RM). These include companies like Canadian success story STEMCELL Technologies, […]

Read More »

Long-Term, 7-Year Study of Nulojix® (belatacept) Regimen Demonstrates Statistically Significant Relative Risk Reduction of Death or Graft Loss over Cyclosporine Regimen in Kidney Transplant

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced results from a 7-year, long-term follow-up from a prospective, randomized Phase III trial (BENEFIT) in kidney transplant patients, which demonstrated a statistically significant 43% relative risk reduction of death or graft loss (transplant failure) in patients receiving the Nulojix (belatacept) FDA-approved dosing regimen over those receiving a […]

Read More »

Integrative Medicine has Positive Impact on Patient Activation, Chronic Pain, Depression

NEW YORK, May 6, 2015 /PRNewswire/ — Integrative medicine interventions lead to significant improvements in patient activation and patient-reported outcomes for chronic pain, depression, and stress, according to a new report released by The Bravewell Collaborative. The findings are based on data collected by the Patients Receiving Integrative Medicine Interventions Effectiveness Registry (PRIMIER), the first-ever patient […]

Read More »

Up to 65 percent of patients with chronic plantar fasciitis may benefit from shock wave therapy

ROSEMONT, Ill., May 6, 2015 /PRNewswire-USNewswire/ — Shock wave therapy may relieve symptoms in up to 65 percent of patients suffering from chronic plantar fasciitis, a common condition causing prolonged pain and discomfort along the bottom of the foot and heel, according to a new study appearing in the May 6 issue of The Journal […]

Read More »

Why Digital Health Has Not (Yet) Transformed Pharmaceutical Drug Development

For the last several years, I’ve been arguing that digital health provides an important opportunity to improve drug development, for several reasons. First, by providing greater insight into the patient’s actual experience of disease, these technologies can reveal important differentiating features of new therapeutics, or point out aspects of illness that new medicines ought to […]

Read More »

Two Under-the-Radar Updates Pfizer (PFE) Investors Need to Know About

Drugmaking behemoth Pfizer Inc. (PFE) had some important information hidden in between the layers Of its first quarter conference call, said a columnist at The Motley Fool on Wednesday, and investors would be wise to take a closer look before parsing out the company’s value. Pfizer had two major updates that could significantly impact its […]

Read More »

Latest draftees could benefit from new-age concussion test

(Reuters) – The 2015 NFL Draft class has now been welcomed into the league, one that could grow safer as their careers unfold through new-age research into identifying concussions. Following a final settlement of a lawsuit brought by former players over concussions that could cost the league $1 billion, and a stunning retirement by a […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom